📊 MTNB Key Takeaways
Is Matinas BioPharma Holdings, Inc. (MTNB) a Good Investment?
Matinas BioPharma is in severe financial distress with revenue collapsing 65.6% YoY to just $1.1M while burning $7M in operating cash flow quarterly. The company's negative gross profit structure, extreme operating margin of -635%, and rapidly depleting cash position indicate an unsustainable business model nearing a critical funding crisis.
Revenue has collapsed and margins remain deeply negative, with operating cash burn far exceeding the company’s $4M cash balance, implying a short runway. Although debt-free with a decent current ratio, fundamentals point to continued losses and a high likelihood of near-term dilution absent meaningful, recurring revenue.
Why Buy Matinas BioPharma Holdings, Inc. Stock? MTNB Key Strengths
- Maintains positive stockholders equity of $4.8M providing limited balance sheet cushion
- Current ratio of 2.79x indicates short-term liquidity to cover immediate liabilities
- Zero long-term debt eliminates refinancing risk
- Debt-free balance sheet
- Solid current ratio (~2.8x)
- Net loss/EPS improved YoY
MTNB Stock Risks: Matinas BioPharma Holdings, Inc. Investment Risks
- Revenue decline of 65.6% YoY signals complete loss of market traction and commercial viability
- Quarterly operating cash burn of $7M with only $4M cash remaining translates to <2 quarters of runway
- Massive negative margins (-943.9% net margin, -635% operating margin) indicate structural unprofitability with no clear path to positive returns
- No insider buying activity in last 90 days suggests management has no confidence in turnaround
- Clinical-stage pharma company with near-zero revenue indicating pipeline failure and failed commercialization
- Short cash runway and dilution risk
- Sharp revenue decline and limited recurring revenue
- Persistently negative margins and ROE
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway
- Pipeline advancement and clinical trial outcomes
- Quarterly revenue stabilization or further deterioration
- Financing activities and dilution events
- Operating expense reduction measures
- Quarterly operating cash burn and runway
- Collaboration/grant revenue (non-dilutive funding)
Matinas BioPharma Holdings, Inc. (MTNB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.79x current ratio provides a solid financial cushion.
MTNB Profit Margin, ROE & Profitability Analysis
MTNB vs Healthcare Sector: How Matinas BioPharma Holdings, Inc. Compares
How Matinas BioPharma Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Matinas BioPharma Holdings, Inc. Stock Overvalued? MTNB Valuation Analysis 2026
Based on fundamental analysis, Matinas BioPharma Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Matinas BioPharma Holdings, Inc. Balance Sheet: MTNB Debt, Cash & Liquidity
MTNB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Matinas BioPharma Holdings, Inc.'s revenue has grown significantly by 592% over the 5-year period, indicating strong business expansion. The most recent EPS of $-4.98 indicates the company is currently unprofitable.
MTNB Revenue Growth, EPS Growth & YoY Performance
MTNB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $1.1M | -$4.3M | $-0.85 |
| Q2 2024 | $1.1M | -$5.7M | $-0.02 |
| Q1 2024 | $1.1M | -$5.5M | $-0.03 |
| Q3 2023 | $1.1M | -$5.5M | $-0.03 |
| Q2 2023 | $1.1M | -$5.9M | $-0.03 |
| Q1 2023 | $1.1M | -$5.5M | N/A |
| Q3 2022 | $33.3K | -$5.5M | N/A |
| Q2 2022 | $33.3K | -$4.8M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Matinas BioPharma Holdings, Inc. Dividends, Buybacks & Capital Allocation
MTNB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Matinas BioPharma Holdings, Inc. (CIK: 0001582554)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MTNB
What is the AI rating for MTNB?
Matinas BioPharma Holdings, Inc. (MTNB) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 87% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MTNB's key strengths?
Claude: Maintains positive stockholders equity of $4.8M providing limited balance sheet cushion. Current ratio of 2.79x indicates short-term liquidity to cover immediate liabilities. ChatGPT: Debt-free balance sheet. Solid current ratio (~2.8x).
What are the risks of investing in MTNB?
Claude: Revenue decline of 65.6% YoY signals complete loss of market traction and commercial viability. Quarterly operating cash burn of $7M with only $4M cash remaining translates to <2 quarters of runway. ChatGPT: Short cash runway and dilution risk. Sharp revenue decline and limited recurring revenue.
What is MTNB's revenue and growth?
Matinas BioPharma Holdings, Inc. reported revenue of $1.1M.
Does MTNB pay dividends?
Matinas BioPharma Holdings, Inc. does not currently pay dividends.
Where can I find MTNB SEC filings?
Official SEC filings for Matinas BioPharma Holdings, Inc. (CIK: 0001582554) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MTNB's EPS?
Matinas BioPharma Holdings, Inc. has a diluted EPS of $-2.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MTNB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Matinas BioPharma Holdings, Inc. has a STRONG SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MTNB stock overvalued or undervalued?
Valuation metrics for MTNB: ROE of -214.2% (sector avg: 15%), net margin of -943.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MTNB stock in 2026?
Our dual AI analysis gives Matinas BioPharma Holdings, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MTNB's free cash flow?
Matinas BioPharma Holdings, Inc.'s operating cash flow is $-7.0M, with capital expenditures of $218.0K. FCF margin is -659.6%.
How does MTNB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -943.9% (avg: 12%), ROE -214.2% (avg: 15%), current ratio 2.79 (avg: 2).